Suppr超能文献

Tip60 通过将雄激素受体易位到细胞核内促进前列腺癌细胞增殖。

Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus.

机构信息

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Prostate. 2010 Apr 1;70(5):540-54. doi: 10.1002/pros.21088.

Abstract

BACKGROUND

There are currently few effective therapies for castration-resistant prostate cancer (CRPCa). CRPC which is resistant to castration is thought to result from increased activation of the androgen/androgen receptor (AR) signaling pathway, which may be augmented by AR coactivators.

METHODS

Luciferase reporter assay, Western blotting, quantitative real-time polymerase chain reaction, fluorescence microscopy, cell proliferation assay, and flow cytometry for cell-cycle analysis were used to resolve a role of Tip60 regulating AR in PCa cells.

RESULTS

Tip60 regulated transcriptions of AR target genes androgen independently. Tip60 knockdown induced translocation of AR into the cytoplasm. Acetylation-mimicking mutations in the nuclear localization signal sequence caused AR protein to mainly localize in the nucleus despite androgen starvation, whereas non-acetylation-mimicking mutations caused AR to mainly localize in the cytoplasm despite androgen stimulation. Tip60 overexpression in castration-resistant LNCaP derivative CxR cells resulted in increases in the acetylated form of AR and AR localization in the nucleus even without androgen. Consequently, Tip60 silencing suppressed the growth of AR-expressing PCa cells by inducing cell-cycle arrest at the G1 phase, similar to inhibition of androgen/AR signaling. Furthermore, Tip60 knockdown suppressed the cell growth of CxR cells.

CONCLUSIONS

Tip60 is involved in the proliferation of PCa cells as an AR coactivator. Modulation of Tip60 expression or function may be a useful strategy for developing novel therapeutics for PCa, even CRPC, which remain dependent on AR signaling, by overexpressing AR and its coactivators.

摘要

背景

目前治疗去势抵抗性前列腺癌(CRPCa)的有效方法较少。去势抵抗性前列腺癌被认为是由于雄激素/雄激素受体(AR)信号通路的激活增加所致,而 AR 共激活剂可能会增强该信号通路的激活。

方法

使用荧光素酶报告基因检测、Western blot、实时定量聚合酶链反应、荧光显微镜、细胞增殖检测和细胞周期分析流式细胞术来确定 Tip60 在前列腺癌细胞中调节 AR 的作用。

结果

Tip60 独立于雄激素调节 AR 的转录。Tip60 敲低诱导 AR 易位到细胞质中。核定位信号序列中的乙酰化模拟突变导致 AR 蛋白即使在去势状态下也主要定位于核内,而非乙酰化模拟突变导致 AR 蛋白即使在雄激素刺激下也主要定位于细胞质中。在去势抵抗性 LNCaP 衍生物 CxR 细胞中转染 Tip60 会导致 AR 的乙酰化形式增加,并使 AR 定位在核内,即使没有雄激素也是如此。因此,Tip60 沉默通过诱导细胞周期停滞在 G1 期抑制 AR 表达的前列腺癌细胞的生长,类似于抑制雄激素/AR 信号。此外,Tip60 敲低抑制了 CxR 细胞的生长。

结论

Tip60 作为 AR 共激活剂参与了前列腺癌细胞的增殖。调节 Tip60 的表达或功能可能是开发新的前列腺癌治疗方法的有效策略,即使是依赖 AR 信号的去势抵抗性前列腺癌,也可以通过过表达 AR 和其共激活剂来实现。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验